Kevin Brodbeck Joins ORIC Pharmaceuticals as Chief Technical Officer

ORIC Pharmaceuticals has appointed Kevin Brodbeck as Chief Technical Officer, bringing over 25 years of experience in technical operations, quality assurance, and regulatory activities. The appointment reflects the company's impending advancement into late-stage development for its clinical programs, ORIC-944 and enozertinib, with Phase 3 trials set to begin in 2026. Brodbeck's role will be crucial in preparing for the potential start of multiple registrational trials and the commercialization of innovative therapies addressing cancer resistance.

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company dedicated to developing treatments that address mechanisms of therapeutic resistance, has appointed Kevin Brodbeck, PhD, as its new Chief Technical Officer (CTO). The appointment comes as the company prepares for the late-stage development of its clinical programs, ORIC-944 and enozertinib (ORIC-114), with Phase 3 trials set to begin in 2026 [1].

Dr. Brodbeck brings over 25 years of experience in technical operations, quality assurance, chemistry, manufacturing and controls (CMC), and regulatory activities. He has held senior leadership positions at Deciphera Pharmaceuticals and Nektar Therapeutics, where he led various development programs and managed global CMC operations [2]. His appointment signals the company's strategic focus on building infrastructure for manufacturing, quality control, and regulatory compliance, which are critical for the success of late-stage clinical trials and eventual commercialization.

The creation of the CTO role and Dr. Brodbeck's appointment reflect ORIC's transition from early/mid-stage clinical development to potential commercialization. As the company approaches the potential initiation of Phase 3 trials next year for ORIC-944 and enozertinib, CMC and Technical Operations will become increasingly critical. Dr. Brodbeck's extensive experience in these areas is expected to provide valuable guidance and leadership in navigating the complex technical requirements for late-stage development and commercialization.

Dr. Brodbeck's background includes expanding Qinlock internationally and preparing Romvimza for regulatory approval in major markets at Deciphera, and leading development programs across multiple therapeutic areas and stages at Nektar Therapeutics. His appointment underscores ORIC's commitment to advancing its clinical programs and addressing the significant challenge of cancer resistance.

The appointment of Dr. Brodbeck as CTO is a strategic move that positions ORIC to meet the rigorous technical demands of late-stage clinical development and commercialization. As the company prepares for the potential start of multiple registrational trials in 2026, Dr. Brodbeck's leadership will be crucial in ensuring the successful advancement of ORIC-944 and enozertinib.

References:
[1] https://www.globenewswire.com/news-release/2025/08/18/3135303/0/en/ORIC-Pharmaceuticals-Expands-Leadership-Team-with-the-Appointment-of-Kevin-Brodbeck-as-Chief-Technical-Officer.html
[2] https://www.stocktitan.net/news/ORIC/oric-pharmaceuticals-expands-leadership-team-with-the-appointment-of-hmwv68829f6t.html